Categories
Change Password!
Reset Password!
Patients with migraine can benefit from low
dose of sodium valproate when used along with magnesium.
As per the outcomes of a randomized trial
published in The Journal of Headache and Pain, magnesium could help boost the anti-migraine characteristics of sodium
valproate when used in a combination therapy and decrease the needed dose of
valproate for migraine prophylaxis.
To estimate the
effectiveness of combination therapy- magnesium and sodium valproate, Samira
Khani et al. included migraine patients aged 18 to 65 years. These patients
with a minimum of 4 attacks in a month were divided
into:
At each monthly visit, migraine features, like
frequency, severity, period of the attacks, and monthly
analgesic usage was noted.
In groups A, B and C, a substantial decrease
in all migraine features compared to those reported at the starting point was
observed. Other than headache frequency, the other three parameters revealed a
noteworthy decrease in group B than group A in the 3rd month.
Additionally, after 3 months, the scores of Headache Impact Test-6 (HIT-6) and Migraine Disability Assessment (MIDAS) considerably decreased in the three groups than those reported at the starting point, with more noteworthy changes in groups A and B as compared to group C as shown in the below figure:
As concluded, this new drug combination can
be used as a more effective and safe treatment for migraine prophylaxis.
The Journal of Headache and Pain
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial
Samira Khani et al.
Comments (0)